Foghorn Therapeutics Inc (FHTX) - Net Assets
Based on the latest financial reports, Foghorn Therapeutics Inc (FHTX) has net assets worth $-108.50 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($198.10 Million) and total liabilities ($306.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FHTX financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-108.50 Million |
| % of Total Assets | -54.77% |
| Annual Growth Rate | N/A |
| 5-Year Change | -212.0% |
| 10-Year Change | N/A |
| Growth Volatility | 32504.69 |
Foghorn Therapeutics Inc - Net Assets Trend (2018–2025)
This chart illustrates how Foghorn Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Foghorn Therapeutics Inc (FHTX) total assets for the complete picture of this company's asset base.
Annual Net Assets for Foghorn Therapeutics Inc (2018–2025)
The table below shows the annual net assets of Foghorn Therapeutics Inc from 2018 to 2025. For live valuation and market cap data, see Foghorn Therapeutics Inc stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-108.50 Million | -138.31% |
| 2024-12-31 | $-45.53 Million | +41.02% |
| 2023-12-31 | $-77.19 Million | -69019.64% |
| 2022-12-31 | $112.00K | -99.88% |
| 2021-12-31 | $96.87 Million | -33.73% |
| 2020-12-31 | $146.19 Million | +266.09% |
| 2019-12-31 | $-88.02 Million | -124.11% |
| 2018-12-31 | $-39.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Foghorn Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 58945900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $6.00K | % |
| Other Components | $523.96 Million | % |
| Total Equity | $-108.50 Million | 100.00% |
Foghorn Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Foghorn Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pizza Pizza Royalty Corp.
TO:PZA
|
$278.88 Million |
|
Jaya Tiasa Holdings Bhd
KLSE:4383
|
$278.90 Million |
|
Sidetrade
PA:ALBFR
|
$278.91 Million |
|
Marine Products Corporation
NYSE:MPX
|
$278.94 Million |
|
Groenlandsbanken AS
CO:GRLA
|
$278.81 Million |
|
Ready Capital Corp
NYSE:RC
|
$278.73 Million |
|
H+H International A/S
CO:HH
|
$278.62 Million |
|
STIF Société anonyme
PA:ALSTI
|
$278.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Foghorn Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -45,528,000 to -108,500,000, a change of -62,972,000.
- Net loss of 74,283,000 reduced equity.
- Other comprehensive income decreased equity by 135,000.
- Other factors increased equity by 11,446,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-74.28 Million | -68.46% |
| Other Comprehensive Income | $-135.00K | -0.12% |
| Other Changes | $11.45 Million | +10.55% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Foghorn Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-2.00 | $4.76 | x |
| 2019-12-31 | $-2.39 | $4.76 | x |
| 2020-12-31 | $3.97 | $4.76 | x |
| 2021-12-31 | $2.61 | $4.76 | x |
| 2022-12-31 | $0.00 | $4.76 | x |
| 2023-12-31 | $-1.84 | $4.76 | x |
| 2024-12-31 | $-0.83 | $4.76 | x |
| 2025-12-31 | $-1.72 | $4.76 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Foghorn Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -240.33%
- • Asset Turnover: 0.16x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-12170.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-22.41 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-42.33 Million |
| 2020 | -47.06% | -16000.00% | 0.00x | 1.75x | $-83.42 Million |
| 2021 | -104.59% | -7681.58% | 0.00x | 5.37x | $-111.01 Million |
| 2022 | -97208.70% | -566.23% | 0.05x | 3615.03x | $-108.88 Million |
| 2023 | 0.00% | -288.17% | 0.12x | 0.00x | $-90.71 Million |
| 2024 | 0.00% | -383.24% | 0.08x | 0.00x | $-82.07 Million |
| 2025 | 0.00% | -240.33% | 0.16x | 0.00x | $-63.43 Million |
Industry Comparison
This section compares Foghorn Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Foghorn Therapeutics Inc (FHTX) | $-108.50 Million | 0.00% | N/A | $278.85 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Foghorn Therapeutics Inc
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is also developing therapies f… Read more